SATB1 and prostate carcinoma: When ZD55-SATB1 was combined with the chemotherapeutic agent Docetaxel (DTX) in human prostate cancer cell lines (DU145 and PC-3), it significantly inhibited cell proliferation, migration, and invasion while promoting apoptosis more effectively than either treatment alone.